Search clinical trials for: GSK233705 12.5mcg

Total 305 results

GlaxoSmithKline

Completed

Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Romania, Bulgaria, Argentina, Canada, Chile, Philippines, South Africa, Thailand, Netherlands, Korea, Republic of, Hungary, United Kingdom
GlaxoSmithKline

Completed

A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD (DB2113373)

Pulmonary Disease, Chronic Obstructive

Japan, Russian Federation, Spain, United States, Bulgaria, Canada, Poland, South Africa, Thailand, Mexico, Chile, Greece, Czechia
GlaxoSmithKline

Completed

A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Estonia, Canada, Chile, Germany, Peru, Philippines, Mexico, Korea, Republic of, Denmark, Russian Federation, Poland, Slovakia
GlaxoSmithKline

Completed

A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Phase I Study of GSK233705 in Healthy Japanese Male Subjects

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Belgium, Sweden
GlaxoSmithKline

Completed

A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses And Oral Dose Of GSK233705

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects

Hepatitis C

United States
GlaxoSmithKline

Completed

Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD (DB2113361)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Ukraine, Estonia, Belgium, France, Sweden, Netherlands, Philippines, Denmark, Hungary, Norway, Slovakia
GlaxoSmithKline

Completed

Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805

Hepatitis C

United States
GlaxoSmithKline

Completed

A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.

Pulmonary Disease, Chronic Obstructive

Netherlands
Baylor Research Institute

Not yet recruiting

Outcomes of Once-Daily ICS/LABA/LAMA Plus PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations (Sundial-COPD)

Copd

United States
Bayer

Completed

Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets

Heart Failure

Germany
Krzysztof Misiukiewicz
Sanofi; Icahn School of Medicine at Mount Sinai

Completed

Cabazitaxel - PF Induction Chemotherapy

Squamous Cell Carcinoma of the Head and Neck

United States
Johns Hopkins University
National Institute on Aging (NIA)

Completed

Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)

Mild Cognitive Impairment (MCI)

United States
GlaxoSmithKline

Completed

A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.

Hepatitis C

United States
Janssen R&D Ireland

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

Healthy

United States
Shire

Completed

Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
University of Dundee

Completed

Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics (MAN05)

Asthma

United Kingdom
University of Palermo
University of Roma La Sapienza

Completed

The Use of Nomegestrol Acetate/Estradiol in Random Start Rapid Endometrial Preparation

Endometrial Polyp | Endometrial Diseases

Italy
GlaxoSmithKline

Completed

28-day Repeat Dose Study of GSK573719

Pulmonary Disease, Chronic Obstructive

United States, Estonia, Germany, Poland
GlaxoSmithKline

Completed

Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Chronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, Idiopathic

Japan
Konkuk University Medical Center

Completed

Propofol Effects on Mitral Valve Annular Velocity

Coronary Artery Disease | Valvular Heart Disease

Korea, Republic of
GlaxoSmithKline
PPD

Completed

Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Hepatitis C, Chronic

Puerto Rico, United States
Shire

Completed

Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD

Attention Deficit Hyperactivity Disorder (ADHD)

United States
HK inno.N Corporation

Completed

A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers

Hypertension

Korea, Republic of
GlaxoSmithKline
PPD

Completed

Dose Ranging of GSK2336805 in Combination Therapy (HAI115879)

Hepatitis C, Chronic

Puerto Rico, United States, Bulgaria, Germany, Belgium, France
Yuhan Corporation

Completed

BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects

Healthy Volunteer

Korea, Republic of
GlaxoSmithKline

Completed

Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults

Hepatitis C

United States
Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults

Solid Tumor | Idiopathic Pulmonary Fibrosis(IPF)

China
GlaxoSmithKline

Completed

Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany
Napo Pharmaceuticals, Inc.

Completed

Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea

Acquired Immunodeficiency Syndrome | HIV/AIDS | Healthy Volunteers | Human Immunodeficiency Virus | HIV Diarrhea

United States
Bayer

Completed

Japanese BAY1000394 Monotherapy Phase I Study

Neoplasms

Japan
Bio-Thera Solutions

Completed

Clinical Study on the Efficacy and Safety of BAT5906 Injection

Wet Age-related Macular Degeneration

China
Annexon, Inc.

Completed

Study of ANX007 in Participants With Primary Open-angle Glaucoma

Open Angle Glaucoma

United States
Wuhan Union Hospital, China
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients

Primary Immune Thrombocytopenia
Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo...

Completed

Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy

Essential Hypertension

Korea, Republic of
GlaxoSmithKline

Completed

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (COPD nDPI)

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Chile, South Africa, Romania, Slovakia
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

Pulmonary Disease, Chronic Obstructive

United States, Germany, Canada, Korea, Republic of
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

Pulmonary Disease, Chronic Obstructive

United States, Korea, Republic of, Chile, Poland, Czech Republic
The Affiliated Hospital of Qingdao University

Completed

A Phase I Clinical Study on SHR6390 in Healthy Chinese Volunteers

Healthy Volunteers

China
Bio-Thera Solutions

Completed

Clinical Study of the Safety and Efficacy of BAT5906 Injection

Diabetic Macular Edema

China
Dong-A ST Co., Ltd.

Completed

The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy

Hypertension

Korea, Republic of
HK inno.N Corporation

Enrolling by invitation

PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects

Healthy

Korea, Republic of
The Affiliated Hospital of Qingdao University

Completed

Bioequivalence of Cefprozil Granule in Healthy Chinese Volunteers

Healthy Volunteers

China
Associação Fundo de Incentivo à Pesquisa
Conselho Nacional de Desenvolvimento Científico e Tecnológico

Unknown

Effects of Zolpidem CR® in Sleep and Heart Recovery in Cardiac Intensive Care Unit Patients

Acute Coronary Syndrome | Sleep Deprivation

Brazil
Suzhou Alphamab Co., Ltd.
Novotech (Australia) Pty Limited

Recruiting

A Study to Evaluate Effects of KN056 in Healthy Participants

Type 2 Diabetes

New Zealand

Search clinical trials for: GSK233705 12.5mcg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations